A method of eliciting an immunogenic response to lyssaviruses comprising intramuscular administration of an immunogenic composition containing inactivated chimeric glycoprotein viruses, wherein said inactivated chimeric glycoprotein viruses comprise components of both RABV and MOKV glycoproteins within a clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain, wherein the clip region is from a MOKV glycoprotein, wherein the core region is from a RABV glycoprotein, wherein the flap region is from a MOKV glycoprotein, and wherein the transmembrane and cytoplasmic domain are from a RABV glycoprotein.